MannKind Corporation
NASDAQ:MNKDBiotechnology
-$0.02 today
- Market cap
- $1.31B
- Beta
- 1.11
- P/E (TTM)
- -50.3
- EPS (TTM)
- -$0.08
Volume 2.12M
Average 5.73M
MNKD Operating Cash Flow
Cash generated by the company's core business operations during the period.
MannKind CorporationNASDAQ: MNKD
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $5.64M (cash outflow) fell 11.5% year over year, ahead of the -36.0% change in trailing-twelve-month operating cash flow. Sequentially, it fell 29.1% from the prior quarter.
Context
- Operating cash flow amounted to 5.2% of revenue in FY2025, down 9.7 pp from a year earlier.
- Operating cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -11.5% holds above the trailing-twelve-month pace of -36.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 18.26M USD
- Year-over-year change
- -57.1%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.26M | -57.1% |
| FY2024 | 2024-12-31 | 42.51M | +24.7% |
| FY2023 | 2023-12-31 | 34.09M | +142.2% |
| FY2022 | 2022-12-31 | (80.7M) | -30.8% |
| FY2021 | 2021-12-31 | (61.71M) | — |
Operating Cash Flow vs competitors
How MNKD compares with its peers on the latest reported figures
- MNKD's LTM Mar 2026 operating cash flow of $18.83M is the 4th largest of the 6 companies compared; the peer median is $8.94M.
- Its year-over-year change of -36.0% is the lowest of 6, against a peer median of +281.7%.
- Operating cash flow amounts to 5.2% of revenue for MNKD, versus a peer median of 210.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $268.78M | +726.4% | — | 244.8% | |
SPRYARS Pharmaceuticals, Inc. | LTM Mar 2026 | $175.07M | +754.7% | +62.1% | 176.9% |
| LTM Mar 2026 | $48.53M | +281.7% | — | 15.4% | |
| LTM Mar 2026 | $18.83M | -36.0% | — | 5.2% | |
| LTM Mar 2026 | $14.93M | +38.8% | -29.2% | 651.0% | |
| LTM Mar 2026 | $8.94M | -14.5% | -31.7% | — | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding MNKD) | $8.94M | +281.7% | -29.2% | 210.9% | |
Competitors are the stored peer set for MNKD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (80.93M) | (87.4M) | (11.94M) | 27.59M | 5.86M |
| Depreciation & Amortization | 5.47M | 6.29M | 5.8M | 9.04M | 12.28M |
| Deferred Income Tax | 12.64M | 0 | 0 | 0 | (4.97M) |
| Stock-Based Compensation | 12.2M | 0 | 17.65M | 21.36M | 24.2M |
| Change in Working Capital | (17.73M) | (24.05M) | 14.63M | (36.47M) | (86.35M) |
| Accounts Receivables | (776K) | (11.81M) | 2.35M | 2.65M | (4.76M) |
| Inventory | (4.08M) | (5.67M) | 4.57M | (3.2M) | 10.4M |
| Accounts Payables | 1.37M | 4.1M | (1.47M) | (2.79M) | (16.71M) |
| Other Working Capital | (14.25M) | (10.67M) | 9.18M | (33.14M) | (75.27M) |
| Other Non-Cash Items | 6.63M | 24.47M | 7.96M | 21M | 67.23M |
| Operating Cash Flow | (61.71M) | (80.7M) | 34.09M | 42.51M | 18.26M |
| Capital Expenditures | (11.47M) | (7.59M) | (42.44M) | (9.69M) | (4.57M) |
| Acquisitions (Net) | (56.06M) | (15.34M) | 0 | 0 | (347.74M) |
| Purchases of Investments | (199.13M) | (5M) | (79.1M) | (273.79M) | (157.8M) |
| Sales of Investments | 59.06M | 0 | 119.17M | 58.13M | 221.72M |
| Other Investing Activities | 56.06M | 32.8M | 382K | 128.71M | (16.41M) |
| Investing Cash Flow | (151.54M) | 4.87M | (1.99M) | (96.65M) | (304.8M) |
| Debt Repayment | 281.08M | (1.09M) | (6.86M) | (133.17M) | 325M |
| Common Stock Issued | 1.89M | 22.56M | 6.89M | (6.09M) | 1.99M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (12.7M) | (62K) | 136.58M | 1.99M | (11.89M) |
| Financing Cash Flow | 270.27M | 21.41M | 136.61M | (137.27M) | 315.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 57.02M | (54.42M) | 168.71M | (191.4M) | 28.55M |
| Free Cash Flow | (73.18M) | (88.29M) | (8.35M) | 32.82M | 13.69M |
MannKind Corporation
NASDAQ:MNKD
Intrinsic Alpha fair value
Locked
Current Price
$4.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.